While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...

The following is a summary of “Advancement and independent validation of a deep learning-based tool for automated scoring of ...

Many people associate psoriatic arthritis (PsA) with itchy, scaly skin and joint pain, but excess fatigue is also a symptom for at least 50% of people with PsA. Fatigue from PsA might be mild ...

Delays in diagnosing and treating psoriatic arthritis – a common inflammatory disorder affecting 112 in every 100,000 adults – are causing irreparable ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

A new study explores gaps in how patients and physicians view psoriatic arthritis (PsA) and recommends ways for clinicians to ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...